Phase II study of a salvage regimen using cyclophosphamide, high‐dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma

Oki, Yasuhiro; Kato, Harumi; Kikuchi, Ako; Taji, Hirofumi; Oshiro, Aya; Tsujimura, Akane; Yamamoto, Kazuhito; Morishima, Yasuo

doi:10.1111/j.1349-7006.2007.00662.x

Cited by 39 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As in some other centers abroad [9][10][11], cytarabine and etoposide containing protocols have been used in China to treat refractory or relapsed lymphoma and MM. Cytarabine and etoposide protocols were available in this study mainly because they have a more intense killing effect on tumor cells than isolated CTX (a traditional sole mobilization agent), and there was no reason to think that this kind of protocol could not achieve better mobilization efficiency than do CTX alone.…”

Section: Discussionmentioning

confidence: 99%

Appropriate timing of G‐CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT

Xu¹,

Chang²,

Li³

et al. 2009

J of Clinical Apheresis

View full text Add to dashboard Cite

The yield of CD34+ cells collected by apheresis for autologous peripheral blood stem cell (PBSC) transplantation was greatly increased when the appropriate timing was determined to begin using G-CSF after COAEP (Cytoxan, Vinblastine, Arabinosylcytosin, Etoposide and Prednisone) mobilization. Twenty-nine patients with lymphoma or multiple myeloma (MM) received the same mobilization chemotherapy, including cytoxan (CTX) 400 mg/m(2) d1; vinblastine (VLB) 2 mg/m(2) d1; Ara-C 60 mg/m(2) x 5d; vp-16 60 mg/m(2) x 5d; and prednisone 40 mg/m(2) x 5d. The historical control group (12 cases) received subcutaneous G-CSF (filgrastim) at the first restoration after the initial nadir of the peripheral WBC count. The experimental group (17 cases) received G-CSF during the steady rise of the WBC count (end of fluctuating after initial nadir). G-CSF was given in a single daily subcutaneous dose of 5 microg/kg until the final PBSC apheresis. When the peripheral WBC and mononuclear cell (MNC) counts reached 10 x 10(9)/L and 1 x 10(9)/L, respectively, leukapheresis was carried out using the COBE Spectrablood cell separator. Despite comparable treatment with alkylating agents, a significantly increased yield of CD34-positive cells was observed in the experimental group (32 x 10(6)/kg) compared with the historical control group (3.1 x 10(6)/kg) (P = 0.0182). This result indicates the importance of appropriate timing for the use G-CSF after mobilization chemotherapy to increase the CD34+ cell yield.

show abstract

Section: Discussionmentioning

confidence: 99%

Appropriate timing of G‐CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT

Xu¹,

Chang²,

Li³

et al. 2009

J of Clinical Apheresis

View full text Add to dashboard Cite

show abstract

“…1-3), relapsed and refractory acute lymphoblastic leukemia (ALL; refs. [4][5][6], and other malignancies (7)(8)(9)(10). The chemotherapeutic efficacy of cytarabine varies dramatically between individuals.…”

Section: Introductionmentioning

confidence: 99%

Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells

et al. 2008

View full text Add to dashboard Cite

To understand the mechanism of cellular resistance to the nucleoside analogue cytarabine (1-B-D-arabinofuranosylcytosine, AraC), two resistant derivatives of the human leukemic line CCRF-CEM were obtained by stepwise selection in different concentrations of AraC. CEM/4ÂAraC cells showed low AraC resistance, whereas CEM/20ÂAraC cells showed high resistance. Both cell lines showed similar patterns of crossresistance to multiple cytotoxic nucleoside analogues, with the exception that CEM/20ÂAraC cells remained sensitive to 5-fluorouridine and 2-deoxy-5-fluorouridine. Both cell lines were sensitive to 5-fluorouracil and to a variety of natural product drugs. Although both CEM/4ÂAraC and CEM/ 20ÂAraC cells displayed reduced intracellular accumulation of [ 3 H]AraC, only CEM/4ÂAraC cells showed reduced uptake of [ 3 H]uridine, which was used to assess nucleoside transport activities. Genes encoding proteins known to be involved in nucleoside transport, efflux, and metabolism were analyzed for the presence of mutations in the two cell lines. In CEM/4ÂAraC cells, independent mutations were identified at each allele of human equilibrative nucleoside transporter 1 (hENT1; SLC29A1), one corresponding to a single-nucleotide change in exon 4, the other being a complex intronic mutation disrupting splicing of exon 13. In contrast to CEM/20ÂAraC cells, CEM/4ÂAraC cells did not bind the hENT1/SLC29A1 ligand nitrobenzylmercaptopurine ribonucleoside and lacked detectable hENT1/SLC29A1 protein. In CEM/20ÂAraC cells, independent intronic mutations impairing splicing of exons 2 and 3 were found at each allele of the deoxycytidine kinase gene. These studies point to at least two distinct mechanisms of AraC resistance in leukemic cells. [Cancer Res 2008;68(7):2349-57]

show abstract

“…Semi-nested PCR was carried 9 (Oki et al 9 ) and R-ESHAP consisting of high-dose cytarabine combination regimens.…”

mentioning

confidence: 99%

Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas

et al. 2011

View full text Add to dashboard Cite

Phase II study of a salvage regimen using cyclophosphamide, high‐dose cytarabine, dexamethasone, etoposide, and rituximab in patients with relapsed or refractory B‐cell non‐Hodgkin's lymphoma

Cited by 39 publications

References 17 publications

Appropriate timing of G‐CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT

Appropriate timing of G‐CSF use after mobilization chemotherapy significantly increases the yield of CD34+ cells in autoPBSCT

Two Distinct Molecular Mechanisms Underlying Cytarabine Resistance in Human Leukemic Cells

Clinical value of flow cytometric immunophenotypic analysis for minimal residual disease detection in autologous stem-cell products of follicular and mantle cell lymphomas

Contact Info

Product

Resources

About